Nuvasive Inc (NUVA) 62.52 $NUVA
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 34.38 (+0.86), NUVA: 62.52 (-0.77)
Buy These 5 Profitable Stocks for Improving Your Returns
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:10AM CDT
Net income ratio reveals the bottom line of a company, by reflecting the percentage of net income to total sales revenue.
FB: 122.76 (-1.55), ENTG: 16.78 (-0.19), TPH: 13.26 (-0.25), AHS: 42.67 (-0.64), NUVA: 62.52 (-0.77)
Michael D. O'Halleran and Patrick S. Miles Elected to NuVasive Board of Directors
Marketwire Canada - Mon Aug 01, 6:00AM CDT
SAN DIEGO, CA--(Marketwired - August 01, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the appointment of Mike O'Halleran and Pat Miles to the Company's Board of Directors effective August 1, 2016. Mr. O'Halleran will serve as an independent director of the Company and member of the Board's Audit Committee. Mr. Miles currently serves as president and chief operating officer (COO) of NuVasive, Inc. and is a member of the Company's executive management team. Mr. Miles will serve as a non-independent member of the Board.
NUVA: 62.52 (-0.77)
Look for Shares of NuVasive to Potentially Rebound after Yesterday's 1.79% Sell Off
Comtex SmarTrend(R) - Wed Jul 27, 3:21PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $59.64 to a high of $62.94. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $61.01 on volume of 999,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NUVA: 62.52 (-0.77)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.18 (-0.25), ZBH: 130.17 (-0.89), GWPH: 94.09 (-2.02), NUVA: 62.52 (-0.77)
Uptrend Call Working As NuVasive Stock Rises 39.5% (NUVA)
Comtex SmarTrend(R) - Wed Jul 27, 12:59PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 5 months, NuVasive has returned 39.54% as of today's recent price of $60.67.
NUVA: 62.52 (-0.77)
Global Market for Regenerative Medicine & Stem Cells - What's hot, what's not, what's next by 2019?
GlobeNewswire - Wed Jul 27, 8:30AM CDT
The competitive landscape of the global regenerative medicine market includes players such as CONMED Corporation, Anika Therapeutics Inc., Arthrex, Inc., Baxter International Inc., Smith & Nephew PLC, DePuySynthes Inc., Stryker Corporation, Medtronic Inc., and Zimmer Holdings Inc. Though North America and Europe were the largest markets for regenerative medicines, the market players are increasingly shifting their focus on the emerging economies across Asia Pacific such as India, South Korea, Japan, and China. These countries are registering an increased demand for various bone and joint reconstructive products such as Osteocel Plus (NuVasive Inc.), Trinity Evolution (Orthofix Inc.), and INFUSE Bone Graft (Medtronic Inc.) owing to the rapid growth of the healthcare sector and the rising pool of patients. The market players are investing in rigorous research and development initiatives for innovative products.
SNN: 33.44 (+0.26), MDT: 87.55 (-0.51), BAX: 48.42 (-0.08), ANIK: 49.55 (-1.09), NUVA: 62.52 (-0.77), SYK: 115.87 (-1.15)
How These Healthcare Stocks are Performing? -- Antares Pharma, Insulet, Globus Medical, and NuVasive
PR Newswire - Wed Jul 27, 7:20AM CDT
Ahead of today's trading session, Stock-Callers.com shifts focus on the Healthcare sector, which is known for its resiliency during downturns. However, current economic conditions are making it difficult for operators to manage their resources and keep up with the increasing demands. We take a look at this morning's picks and assess their performances at the close on Tuesday, July 26, 2016: Antares Pharma Inc. (NASDAQ: ATRS), Insulet Corp. (NASDAQ: PODD), Globus Medical Inc. (NYSE: GMED), and NuVasive Inc. (NASDAQ: NUVA). Learn more about these stocks by accessing their freenotes at:
PODD: 35.29 (-0.09), GMED: 23.61 (+0.12), NUVA: 62.52 (-0.77), ATRS: 1.01 (-0.02)
NuVasive Reports Second Quarter 2016 Financial Results
Marketwire Canada - Tue Jul 26, 3:02PM CDT
Company Delivers Double-Digit Revenue Growth and Increases Full Year 2016 Guidance
NUVA: 62.52 (-0.77)
Chemed (CHE) Lags Q2 Earnings, Tops Revenues, View Up
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:59AM CDT
Chemed???s (CHE) second-quarter 2016 results were a mixed bag with its bottom-line lagging behind the Zacks Consensus Estimate while revenues exceeded the same
CHE: 145.71 (-1.36), BSX: 24.18 (-0.25), NUVA: 62.52 (-0.77)
Baxter International (BAX) Q2 Earnings, Sales Top; View Up
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:25AM CDT
Baxter International Inc (BAX) reported second-quarter 2016 adjusted earnings of 46 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents.
BSX: 24.18 (-0.25), BAX: 48.42 (-0.08), BXLT: 46.02 (-0.18), NUVA: 62.52 (-0.77)
Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:24PM CDT
Alere Inc. (ALR) lowered revenue estimate for the year that ended on Dec 31, 2015 and also offered some Q1 figures.
BSX: 24.18 (-0.25), ABT: 45.07 (-0.22), ALR: 36.12 (-0.85), NUVA: 62.52 (-0.77)
Will AmSurg's Merger with Envision Healthcare Drive Growth?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:08PM CDT
AmSurg (AMSG) recently agreed to merge in an all-stock deal with Envision Healthcare to create one of the largest providers of physician services in the U.S.
AMSG: 71.29 (-0.94), BSX: 24.18 (-0.25), EVHC: 23.31 (-0.28), GWPH: 94.09 (-2.02), NUVA: 62.52 (-0.77)
The Zacks Analyst Blog Highlights: NuVasive, Apogee Enterprises, Burlington Stores, Newfield Exploration and Saratoga Investment
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 8:30AM CDT
The Zacks Analyst Blog Highlights: NuVasive, Apogee Enterprises, Burlington Stores, Newfield Exploration and Saratoga Investment
NFX: 41.19 (-0.10), SAR: 16.99 (-0.14), APOG: 46.52 (-0.31), BURL: 73.71 (-2.63), NUVA: 62.52 (-0.77)
Medtronic's IN.PACT Admiral DCB Wins FDA Nod for 150 mm
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 6:22AM CDT
With Medtronic (MDT)being a major player in the medical devices market, surely the FDA approval will accelerate the demand for its peripheral therapy products.
BSX: 24.18 (-0.25), MDT: 87.55 (-0.51), GWPH: 94.09 (-2.02), NUVA: 62.52 (-0.77)
Buy 5 Momentum Picks That Brokers Love
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 3:35PM CDT
When sustainable development is a matter of question, the ideal investment strategy is to go for momentum stocks.
NFX: 41.19 (-0.10), SAR: 16.99 (-0.14), APOG: 46.52 (-0.31), BURL: 73.71 (-2.63), NUVA: 62.52 (-0.77)
Upgrade Alert for NuVasive (NUVA)
Comtex SmarTrend(R) - Thu Jul 14, 3:29AM CDT
NuVasive (NASDAQ:NUVA) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $61.42 on volume of 769,000 shares, above average daily volume of 754,000. NuVasive, Inc. designs, develops, and markets products for the surgical treatment of spine disorders. The Company's products include Maximum Access Surgery (MAS) and Fusion products.
NUVA: 62.52 (-0.77)
Strength seen in Haemonetics (HAE): Stock Soars 10.5%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:30AM CDT
Haemonetics Corporation (HAE) shares rose over 11% in the last trading session.
HAE: 34.38 (+0.86), NUVA: 62.52 (-0.77)
Buy These 5 Profitable Stocks for Improving Your Returns
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:10AM CDT
Net income ratio reveals the bottom line of a company, by reflecting the percentage of net income to total sales revenue.
FB: 122.76 (-1.55), ENTG: 16.78 (-0.19), TPH: 13.26 (-0.25), AHS: 42.67 (-0.64), NUVA: 62.52 (-0.77)
Michael D. O'Halleran and Patrick S. Miles Elected to NuVasive Board of Directors
Marketwire Canada - Mon Aug 01, 6:00AM CDT
SAN DIEGO, CA--(Marketwired - August 01, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the appointment of Mike O'Halleran and Pat Miles to the Company's Board of Directors effective August 1, 2016. Mr. O'Halleran will serve as an independent director of the Company and member of the Board's Audit Committee. Mr. Miles currently serves as president and chief operating officer (COO) of NuVasive, Inc. and is a member of the Company's executive management team. Mr. Miles will serve as a non-independent member of the Board.
NUVA: 62.52 (-0.77)
Look for Shares of NuVasive to Potentially Rebound after Yesterday's 1.79% Sell Off
Comtex SmarTrend(R) - Wed Jul 27, 3:21PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $59.64 to a high of $62.94. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $61.01 on volume of 999,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NUVA: 62.52 (-0.77)
NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.18 (-0.25), ZBH: 130.17 (-0.89), GWPH: 94.09 (-2.02), NUVA: 62.52 (-0.77)
Uptrend Call Working As NuVasive Stock Rises 39.5% (NUVA)
Comtex SmarTrend(R) - Wed Jul 27, 12:59PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 5 months, NuVasive has returned 39.54% as of today's recent price of $60.67.
NUVA: 62.52 (-0.77)
Global Market for Regenerative Medicine & Stem Cells - What's hot, what's not, what's next by 2019?
GlobeNewswire - Wed Jul 27, 8:30AM CDT
The competitive landscape of the global regenerative medicine market includes players such as CONMED Corporation, Anika Therapeutics Inc., Arthrex, Inc., Baxter International Inc., Smith & Nephew PLC, DePuySynthes Inc., Stryker Corporation, Medtronic Inc., and Zimmer Holdings Inc. Though North America and Europe were the largest markets for regenerative medicines, the market players are increasingly shifting their focus on the emerging economies across Asia Pacific such as India, South Korea, Japan, and China. These countries are registering an increased demand for various bone and joint reconstructive products such as Osteocel Plus (NuVasive Inc.), Trinity Evolution (Orthofix Inc.), and INFUSE Bone Graft (Medtronic Inc.) owing to the rapid growth of the healthcare sector and the rising pool of patients. The market players are investing in rigorous research and development initiatives for innovative products.
SNN: 33.44 (+0.26), MDT: 87.55 (-0.51), BAX: 48.42 (-0.08), ANIK: 49.55 (-1.09), NUVA: 62.52 (-0.77), SYK: 115.87 (-1.15)
How These Healthcare Stocks are Performing? -- Antares Pharma, Insulet, Globus Medical, and NuVasive
PR Newswire - Wed Jul 27, 7:20AM CDT
Ahead of today's trading session, Stock-Callers.com shifts focus on the Healthcare sector, which is known for its resiliency during downturns. However, current economic conditions are making it difficult for operators to manage their resources and keep up with the increasing demands. We take a look at this morning's picks and assess their performances at the close on Tuesday, July 26, 2016: Antares Pharma Inc. (NASDAQ: ATRS), Insulet Corp. (NASDAQ: PODD), Globus Medical Inc. (NYSE: GMED), and NuVasive Inc. (NASDAQ: NUVA). Learn more about these stocks by accessing their freenotes at:
PODD: 35.29 (-0.09), GMED: 23.61 (+0.12), NUVA: 62.52 (-0.77), ATRS: 1.01 (-0.02)
NuVasive Reports Second Quarter 2016 Financial Results
Marketwire Canada - Tue Jul 26, 3:02PM CDT
Company Delivers Double-Digit Revenue Growth and Increases Full Year 2016 Guidance
NUVA: 62.52 (-0.77)
Chemed (CHE) Lags Q2 Earnings, Tops Revenues, View Up
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:59AM CDT
Chemed???s (CHE) second-quarter 2016 results were a mixed bag with its bottom-line lagging behind the Zacks Consensus Estimate while revenues exceeded the same
CHE: 145.71 (-1.36), BSX: 24.18 (-0.25), NUVA: 62.52 (-0.77)
Baxter International (BAX) Q2 Earnings, Sales Top; View Up
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:25AM CDT
Baxter International Inc (BAX) reported second-quarter 2016 adjusted earnings of 46 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents.
BSX: 24.18 (-0.25), BAX: 48.42 (-0.08), BXLT: 46.02 (-0.18), NUVA: 62.52 (-0.77)
Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:24PM CDT
Alere Inc. (ALR) lowered revenue estimate for the year that ended on Dec 31, 2015 and also offered some Q1 figures.
BSX: 24.18 (-0.25), ABT: 45.07 (-0.22), ALR: 36.12 (-0.85), NUVA: 62.52 (-0.77)
Will AmSurg's Merger with Envision Healthcare Drive Growth?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:08PM CDT
AmSurg (AMSG) recently agreed to merge in an all-stock deal with Envision Healthcare to create one of the largest providers of physician services in the U.S.
AMSG: 71.29 (-0.94), BSX: 24.18 (-0.25), EVHC: 23.31 (-0.28), GWPH: 94.09 (-2.02), NUVA: 62.52 (-0.77)
The Zacks Analyst Blog Highlights: NuVasive, Apogee Enterprises, Burlington Stores, Newfield Exploration and Saratoga Investment
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 8:30AM CDT
The Zacks Analyst Blog Highlights: NuVasive, Apogee Enterprises, Burlington Stores, Newfield Exploration and Saratoga Investment
NFX: 41.19 (-0.10), SAR: 16.99 (-0.14), APOG: 46.52 (-0.31), BURL: 73.71 (-2.63), NUVA: 62.52 (-0.77)
Medtronic's IN.PACT Admiral DCB Wins FDA Nod for 150 mm
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 6:22AM CDT
With Medtronic (MDT)being a major player in the medical devices market, surely the FDA approval will accelerate the demand for its peripheral therapy products.
BSX: 24.18 (-0.25), MDT: 87.55 (-0.51), GWPH: 94.09 (-2.02), NUVA: 62.52 (-0.77)
Buy 5 Momentum Picks That Brokers Love
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 3:35PM CDT
When sustainable development is a matter of question, the ideal investment strategy is to go for momentum stocks.
NFX: 41.19 (-0.10), SAR: 16.99 (-0.14), APOG: 46.52 (-0.31), BURL: 73.71 (-2.63), NUVA: 62.52 (-0.77)
Upgrade Alert for NuVasive (NUVA)
Comtex SmarTrend(R) - Thu Jul 14, 3:29AM CDT
NuVasive (NASDAQ:NUVA) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $61.42 on volume of 769,000 shares, above average daily volume of 754,000. NuVasive, Inc. designs, develops, and markets products for the surgical treatment of spine disorders. The Company's products include Maximum Access Surgery (MAS) and Fusion products.
NUVA: 62.52 (-0.77)
